189 related articles for article (PubMed ID: 34454680)
1. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; ; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C
Gynecol Oncol; 2021 Sep; 162(3):720-727. PubMed ID: 34454680
[TBL] [Abstract][Full Text] [Related]
2. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Roussel-Simonin C; Blanc-Durand F; Tang R; Vasseur D; Le Formal A; Chardin L; Yaniz E; Gouy S; Maulard A; Scherier S; Sanson C; Lacroix L; Cotteret S; Mauny L; Zaccarini F; Rouleau E; Leary A
Mol Cancer; 2023 Nov; 22(1):178. PubMed ID: 37932736
[TBL] [Abstract][Full Text] [Related]
4. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract][Full Text] [Related]
5. Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.
Waki K; Yokomizo K; Kawano K; Tsuda N; Komatsu N; Yamada A
Cancer Immunol Immunother; 2020 Oct; 69(10):2001-2007. PubMed ID: 32393999
[TBL] [Abstract][Full Text] [Related]
6. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.
Barbosa A; Peixoto A; Pinto P; Pinheiro M; Teixeira MR
Expert Rev Mol Med; 2018 Dec; 20():e6. PubMed ID: 30558693
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient.
Zhou S; Xu B; Qi L; Zhu D; Liu B; Wei J
Cancer Biol Ther; 2019; 20(1):15-20. PubMed ID: 30118648
[TBL] [Abstract][Full Text] [Related]
8. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
Miller BF; Pisanic Ii TR; Margolin G; Petrykowska HM; Athamanolap P; Goncearenco A; Osei-Tutu A; Annunziata CM; Wang TH; Elnitski L
Clin Epigenetics; 2020 Oct; 12(1):154. PubMed ID: 33081832
[TBL] [Abstract][Full Text] [Related]
9. Refined characterization of circulating tumor DNA through biological feature integration.
Markus H; Chandrananda D; Moore E; Mouliere F; Morris J; Brenton JD; Smith CG; Rosenfeld N
Sci Rep; 2022 Feb; 12(1):1928. PubMed ID: 35121756
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
[TBL] [Abstract][Full Text] [Related]
11. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers.
Yamamoto CM; Oakes ML; Murakami T; Muto MG; Berkowitz RS; Ng SW
J Ovarian Res; 2018 Mar; 11(1):20. PubMed ID: 29499737
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
13. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE
Transl Oncol; 2024 May; 43():101914. PubMed ID: 38417292
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
[TBL] [Abstract][Full Text] [Related]
16. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer.
Wang W; Jo H; Park S; Kim H; Kim SI; Han Y; Lee J; Seol A; Kim J; Lee M; Lee C; Dhanasekaran DN; Ahn T; Song YS
Cancer Lett; 2022 Aug; 542():215735. PubMed ID: 35569696
[TBL] [Abstract][Full Text] [Related]
18. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
20. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]